# Omega-3 fatty acids and dementia ☆

Greg M. Cole [a,b,c,*], Qiu-Lan Ma [a,c], Sally A. Frautschy [a,b,c]

[a] Department of Medicine at University of California, Los Angeles, CA, USA
[b] Department of Neurology at University of California, Los Angeles, CA, USA
[c] GRECC Veterans Affairs, Greater Los Angeles Healthcare System, Research-151, Building 7, Room A101, 16111 Plummer Street, North Hills, CA 91343, USA

## ARTICLE INFO

## ABSTRACT

More than a dozen epidemiological studies have reported that reduced levels or intake of omega-3 fatty acids or fish consumption is associated with increased risk for age-related cognitive decline or dementia such as Alzheimer's disease (AD). Increased dietary consumption or blood levels of docosahexaenoic acid (DHA) appear protective for AD and other dementia in multiple epidemiological studies; however, three studies suggest that the ApoE4 genotype limits protection. DHA is broadly neuroprotective via multiple mechanisms that include neuroprotective DHA metabolites, reduced arachidonic acid metabolites, and increased trophic factors or downstream trophic signal transduction. DHA is also protective against several risk factors for dementia including head trauma, diabetes, and cardiovascular disease. DHA is specifically protective against AD via additional mechanisms: It limits the production and accumulation of the amyloid β peptide toxin that is widely believed to drive the disease; and it also suppresses several signal transduction pathways induced by Aβ, including two major kinases that phosphorylate the microtubule-associated protein tau and promote neurofibrillary tangle pathology. Based on the epidemiological and basic research data, expert panels have recommended the need for clinical trials with omega-3 fatty acids, notably DHA, for the prevention or treatment of age-related cognitive decline—with a focus on the most prevalent cause, AD. Clinical trials are underway to prevent and treat AD. Results to-date suggest that DHA may be more effective if it is begun early or used in conjunction with antioxidants.

Published by Elsevier Ltd.

## 1. Introduction

Alzheimer's disease (AD) and other late life dementias double every 5 years after age 65. Some 80 million baby boomers are rapidly approaching this age in the US, and similar demographic shifts toward aging populations are occurring throughout the world. Until methods of preventing AD are found, it is not only the tens of millions of disease victims and their families that will suffer, but also our nation, our Medicare system, and our economy as whole. While genetics plays the major role in risk for familial AD with early onset, the majority of AD is late onset and appears to involve the interplay of multiple genetic and environmental risk factors [1]. These interact to modulate the pathogenesis and risk of late onset AD, but are not sufficiently powerful to act alone to determine outcomes. Among the environmental risk factors, increased consumption of fish/omega-3 fatty acids (this review),

antioxidants [2], and non-steroidal anti-inflammatory drugs [3] are associated with reduced risk for AD. Based on this, our group and others have tested supplementation with the omega-3 fatty acid DHA, antioxidants, and NSAIDs in animal models for the treatment of AD. NSAIDs reduce amyloid accumulation in multiple models, but have toxicity issues, including GI bleeds and increased risk of cardiovascular events, that limit use for prevention [4]. In contrast, omega-3 fatty acids are not only relatively inexpensive, but have an excellent safety profile and are proven to reduce cardiovascular disease mortality by 37% [5,6]. If omega-3 fatty acids can be proven to slow pathogenesis of AD and reduce AD risk, they would be an ideal intervention approach. Here we review the evidence for their efficacy.

## 2. Omega-3 fatty acids/DHA reduce risk for Alzheimer's disease and other dementia

Omega-3 fatty acids exert pleiotropic effects on the cardiovascular and central nervous systems (CNS) that may be protective against age-related cognitive decline, where the causes are either vascular or Alzheimer dementia or a mix of both. Low omega-3 fatty acid intake is one of many overlapping risk factors for both

cardiovascular disease (CVD) and AD that include diabetes, hypercholesterolemia, hypertension, hyperhomocysteinemia, dietary saturated fats, cholesterol, antioxidants, alcohol consumption, smoking, physical activity, the presence of atrial fibrillation, and atherosclerotic disease [7]. Although low omega-3 fatty acid intake is only one of many risk factors, it matters. For example, recent meta-analysis indicates that omega-3 fatty acids from fish can provide a 36% reduction in an unambiguous, endpoint-death from coronary artery disease [8]. The cardiovascular protective effects of omega-3 fatty acids are backed by repeated positive clinical trial results, which lead to practical recommendations for dietary supplementation [9], but clinical trials for dementia prevention have not been concluded. Nevertheless, a 2005 literature evidence-based meta-analysis on omega-3 fatty acids and dementia, requested by the US Department of Health and Human Services, concluded that there was sufficient evidence to merit clinical trials for the treatment and prevention of AD [10]. Since then, the results of a number of new studies have been reported. Nine epidemiological studies now support that increased dietary intake of fish is associated with reduced risk for cognitive decline or dementia (Table 1). Several of the studies show a 40–50% reduced risk of dementia. Curiously, two results found no effect in subjects with a major AD genetic risk factor, the ApoE4 allele of apolipoprotein E. Because ApoE4 is found in ~40–50% of AD patients, a lack of response in ApoE4 cases would account for many of the apparent "non-responders" in epidemiological studies approaching 50% risk reduction. However, not all reports show the same ApoE genotype effect on omega-3 fatty acid response.

One potential confounding factor in epidemiological studies might be limited reliability in dietary survey data. However, there have been another eight studies in which high blood levels of omega-6 (relative to omega-3) fatty acids were associated with AD and/ or increased cognitive decline (Table 2). In general, these studies show protection from omega-3 fatty acids, confirming the results based on dietary intake estimates. The prospective Framingham study from Schaefer et al. [11] is notable in that blood levels taken at ~10 years prior to assessment of cognitive status showed protection from dementia or AD (average age 76 years) in the group with the upper 25% quartile blood DHA levels. No other lipid was predictive of risk. The authors estimated a daily intake of 180 mg per day of DHA in the protected group and plasma DHA levels correlated with fish intake. However, estimated daily intakes of DHA from fish accounted for only half the variance suggesting involvement of genetic factors or other n-3, notably alpha linolenic acid (ALA). In an atherosclerosis risk study from Minnesota that followed cognitive decline in younger patients with less AD risk (age 50–65 years), Beydoun et al. [12] found that higher plasma omega-3 fatty acid levels were associated with less decline in verbal fluency, particularly in hypertensive and dyslipidemic patients. They reported these patients as having more oxidative stress, which might deplete the highly peroxidizable long chain omega-3 fatty acids (omega-3 or n-3). Alternatively, because of the overlap between AD and CVD risk factors, protection against decline in midlife may involve reduction in both incipient vascular and Alzheimer dementia accelerated by hypertension and elevated blood lipids. In the same study and in others, high blood levels of omega-6 fatty acids (n-6) were associated with increased risk, consistent with the protective value of a low n-6/n-3 ratio. Supporting a possible association between omega-3 fatty acid levels and oxidative stress, Wang et al. [13] (Table 2) found an association between a high RBC n-3 index and levels of several lipid soluble antioxidants. The prospective blood level study of Whalley et al. [14] again reported less protection from high omega-3 fatty acid in ApoE4 carriers. ApoE4 carriers show evidence of increased oxidative stress, including lipid peroxidation products [15,16], consistent with a large literature showing that ApoE4 increases susceptibility to oxidative stress in animal and cell culture experiments (reviewed in [17]). Thus, one logical explanation for a possible interaction between omega-3 fatty acids and ApoE4 genotype would be increased lipid peroxidation.

**Table 1**
Dietary fish reduces AD risk (9 positive studies).

| Study | Population | Methods | Findings | Other |
|---|---|---|---|---|
| Kalmijn et al. [70] | Zutphen N = 476 men, 64–89 years | Diet history, MMSE | Fish intake reduced in 153 impaired men, but n-3 not associated with 3-year cognitive decline | Fish intake inversely correlated with cognitive decline (adjusted OR = 0.45, p = 0.09); linoleic acid raised risk. |
| Kalmijn et al. [71] | Rotterdam, N = 5386, 55+ years | Diet history, dementia | High fish, RR (D) = 0.4; RR (AD) = 0.3 | Saturated fat and cholesterol increased risk |
| Morris et al. [72] | Chicago, N = 815 unimpaired, 65–94 years | Diet history, 2.3 years follow-up test for AD | 131/815 developed AD, 60% less risk of AD with fish | DHA but not EPA associated with low AD risk |
| Kalmijn et al. [73] | Zutphen N = 1613, 45–70 years | Diet history, Cog testing | High n-3 reduces risk of cognitive impairment | Cholesterol and sat. fat increased risk |
| Morris et al. [74] | Chicago, N = 3718 65+, mean 74 years | Diet history, Cog testing | Fish consumption associated with reduced cognitive decline over 6 years | No clear association with n-3 intake |
| Huang et al. [75] | Boston | Diet history, Dementia/ AD | Fish consumption reduces AD risk by 41%, dementia by 28% | Risk reduction only in non-ApoE4 |
| Nurk et al. [76] | Norway, N = 2031, 70–74 years | Diet history, Cog testing | Less than 10 g/day fish intake predicts poor Cog performance | Most Cog function improved dose-dependently up to 75 g/d fish |
| Barberger-Gateauet al. [77] | France, 3-City, N = 8085, non-demented, 65+ years | Diet history, 4 years follow-up, Dementia/AD | 281 dementia (183 AD) Fish reduced dementia (HR = 0.46) and AD (HR = 0.65) | Fish only protective for AD in non-ApoE4 (HR = 0.60) |
| van Gelder et al. [78] | Zutphen, (N = 210, men 70–89 years) | Diet history, 5 years follow-up, MMSE | ~400 mg/day DHA+EPA associates with reduced decline | Dose-dependent effect |

*Abbreviations*: Cog, cognitive; DHA, docosahexaenoic acid; EPA, eicosapentanoic acid; HR, hazard ratio; MMSE, mini-mental status examination; OR, odds ratio. Sat., saturated.

**Table 2**
Blood omega-3 fatty acids and cognitive decline (8/10 positive studies).

| Study | Population | Methods | Findings | Other |
|---|---|---|---|---|
| Conquer et al. [79] | Canada, $N = 55$ 77–83 years | Plasma PL, Cog testing | Low plasma n-3 in AD and Cog-impaired aged | Higher n-6 and lower n-3/n-6 in AD or impaired |
| Heude et al. [80] | France-EVA, $N = 246$ 63–74 years baseline | RBC, 4 years follow-up, MMSE | High n-3 predicts reduced decline (OR = 0.59) | High n-6, n-6/n-3 predicts more decline |
| Laurin et al. [81] | Canada, 65+ years | Plasma PL | Higher DHA in dementia cases | Unchanged n-3 in AD |
| Schaefer et al. [11] | Framingham, $N = 899$ unimpaired, Median 76 years, prospective | Plasma PL, 9.1 years follow-up Dementia/AD | 99/899 got dementia, 71 AD, high quartile DHA, RR = 0.53 dementia 0.61 AD | 3 servings/ week in high DHA quartile |
| Dullemeijer et al. [82] | Holland FACIT (folic acid) trial, $N = 807$, 50–70 years cross-section | Plasma PL, Cog testing | High n-3 predicts less decline in sensorimeter and complex speed over 3 years | Plasma n-3 did not predict 3-year changes in memory, information-processing speed, or word fluency. |
| Beydoun et al. [12,83] | Minneapolis, ($N = 2251$, 50–65 years) | Plasma PL/chol. Esters. Cog testing, 6 years follow-up | 140 decline, higher n-3 reduces risk of decline in verbal fluency | Effects stronger w/ hypertension/ dyslipid-emia, important in middle age (low n-3/n-6 trend, $p = 0.09$) |
| Cherubini et al. [84] | Chianti, Italy, $N = 935$, Mean age 75.6 years | Plasma, MMSE | n-3 levels reduced with cognitive deficits | |
| Tully et al. [85] | Dublin, $N = 148$ AD (76.5 years), 45 (70 years) controls | Serum cholesterol-ester DHA | DHA significantly reduced in all AD | DHA levels reduced with dementia severity |
| Wang et al. [13] | Oregon, $N = 46$, AD+controls | RBC DHA | MMSE directly correlates with RBC n-3 index | Lower DHA and antioxidants associate |
| Whalley et al. [14] | England, $N = 120$, born in 1936, age 64–68 years | RBC DHA | High RBC DHA associated with better cognitive function | Significant only in non-Apo E4 |

*Abbreviations*: chol., cholesterol; Cog, cognitive; EVA, Etude sur le Vieillissement Arteriel; FACIT, folic acid and carotid intima-media thickness; PL, phospholipids; RR, relative risk; RBC, red blood cells.

In summary, in the 3 years since the 2005 evidence-based review of the omega-3 fatty acid and dementia-related literature, the results of eight new studies have added further support to the 2005 conclusions, which called for randomized clinical trials that are: (1) sufficiently powered, (2) of an adequate length (e.g., 3–5 years of follow-up), (3) early intervention during "the lengthy presymptomatic latency period" as well as (4) in populations of cognitively impaired adults, prior to a dementia diagnosis, such as individuals with various sub-types of mild cognitive impairment (MCI) [10].

### 3. The Western diet is omega-3 deficient

The dietary intake and blood level studies in Tables 1 and 2 suggest a consistent reduction in risk for cognitive decline, AD, or other dementia for those in the upper quartiles or quintiles of omega-3 intake or blood levels. To be in this protected group based on epidemiology would require ∼200 mg DHA daily intake. Consistent with these studies, this is much higher than the average US daily intake, which is generally estimated to be closer to ∼80 mg—or less than half that in the low-dementia risk groups. Perhaps because the risk factors are shared, these numbers are similar to those arising from the epidemiology for reducing CVD risk; however, the explanation for DHA-reduced dementia and AD risk likely involves more than that for reduced CVD and multiple effects, including neuroprotection and more specific effects on AD pathogenesis.

### 4. Alzheimer (AD) pathogenesis

AD is believed to be caused by increased amyloid β (Aβ1-42) protein, which is derived from a larger β amyloid precursor protein, by sequential endoproteolysis catalyzed by enzymes called β- and γ- secretase. Aβ 1-42 aggregates to form neurotoxic oligomers and fibrils [1]. These oligomers and fibrils of Aβ can cause oxidative damage, neuroinflammation, and synaptic dysfunction; as well as loss and activation of different kinases that phosphorylate tau protein and promote its aggregation into toxic species, including soluble tau oligomers and intraneuronal neurofibrillary tangles. While Aβ may initiate pathogenesis, tau pathology is a better correlate of neurodegeneration and progression, and synapse loss is the best correlate of cognitive decline [18].

### 5. DHA is neuroprotective via multiple mechanisms

**1. Reducing arachidonic acid and its metabolites**: The omega-3 fatty acid DHA is preferentially taken up by the brain, where it is highly enriched in neurons and synapses, and esterified at the second position of phospholipids. While many effects relevant to CNS function have been reported [19], a subset of these shown in Table 3 and Fig. 1 would be predicted to be neuroprotective and relevant to Alzheimer and other dementia diseases. For example, because DHA and arachidonic acid (AA) compete for esterification into phospholipids at the most labile sites, higher ratios of n-3/n-6 intake reduce the flux of AA released by phospholipases, which are activated during glial or synaptic signaling, notably by calcium influx. In AD, there is both an overall pattern of chronic low-level inflammation [20] and excitotoxic activity [21], resulting in elevated COX-2 [22,23], increased AA products including cyclooxygenase products like PGE2 [24], and lipoxygenase products [25,26]. Increased DHA influx has the potential to reduce AA availability, particularly in compartments with higher lipid metabolism that contribute to both glial and neuronal hyperactivation. Reduced AA has been observed in brains of DHA-fed AD model mice with a positive response [27–29]. Thus, DHA should share some neuroprotective mechanisms with NSAIDs, for example, COX-2 [30] and lipoxygenase [26] inhibitors. If a significant part of DHA's protective activity stems in part from NSAID-like activity, this is noteworthy because, while NSAIDs reduce Alzheimer risk in most epidemiology, the protective effects are not seen with use only in the 2–3 years prior to assessment and are much clearer when there is 5 or more years duration of use [31]. This "lagging" or

**Table 3**
Neuroprotective effects of DHA.

| Neuroprotective effect | References |
| --- | --- |
| (1) Anti-inflammatory. Reducing AA and metabolites via COX and lipoxygenase (PG, HETES, etc.) | [86–88] |
| (2) Insulin/trophic factor potentiation via Akt | [32] |
| (3) Increased brain-derived neurotrophic factor | [34,89] |
| (4) Antioxidant. Direct (?). Increasing AO enzymes (catalase, GSH peroxidase) | [90–92] |
| (5) Anti-apoptotic. Increasing NPD1, anti-apoptotic& reducing pro-apoptotic proteins | [41,93] |
| (6) Promotes neurogenesis | [94] |
| (7) Increasing a glucose transporter | [95,96] |
| (8) Coupling blood flow to glucose utilization | [95,96] |
| (9) Improving synaptic membrane fluidity | [97] |
| (10) Increasing G-protein coupling | [98] |
| (11) PPAR or RXR agonists | [42,99] |

*Abbreviations*: AO, antioxidant; AA, arachidonic acid; COX, cyclooxygenase; GSH, reduced glutathione; HETE, hydroxyeicosatetraenoic acids; PG, prostaglandins; NPD1, neuroprotectin D1; PPAR, peroxisome proliferators-activated receptor; RXR, retinoid X receptor.



**Fig. 1.** Summary of mechanisms of anti-Alzheimer effects of DHA. As reviewed in Tables 3 and 4, DHA has multiple-reported neuroprotective and anti-Aβ effects. These include reducing Aβ production by increasing SorLA/LR11, and non-amyloidogenic processing of amyloid precursor and decreasing γ-secretase. Aβ clearance may be improved by induction of transthyretin or IDE. The DHA metabolite NPD1 can also be neuroprotective by reducing pro-apoptotic proteins such as Bad. Further, DHA increases in PS and PDK/AKT docking will potentiate neuroprotective trophic factor signaling through insulin, IGF1, BDNF, and other trophic factors. BDNF itself is induced by DHA. Downstream from AKT, there are anti-apoptotic effects on Bad and caspases, and up-regulation of the Nrf2 pathway to ARE and antioxidant defense enzymes. Further, the major tau kinase GSK3 will be inhibited, limiting tau/tangles, which may also contribute to reduced Aβ production. Finally, one *in vivo* report found DHA-limited activation of another tau kinase (JNK) and accumulation of tau pathology.

delayed protection is obviously a problem for clinical trials, where duration is a major expense.

**2. Trophic factor signaling**: A second mechanism for neuroprotective activity for DHA involves potentiating the activation of one branch of classical neurotrophic factor (BDNF, NGF, bFGF) or insulin signaling via the phosphatidylinositol-3 kinase (PI3-K)>Akt pathway. DHA increases neuronal phosphatidylserine (PS) and the rate of a critical activation step: Akt membrane docking, which occurs through a plecstrin homology domain

pocket that binds the PI3-K product PIP3 and PS [32]. The net effect is to increase neurotrophic signaling to down-regulate pro-apoptotic regulators of caspases like Bad that control cell death. Some evidence for this activity was found with elevated inactivation of Bad and reduced caspase activation in AD model mice fed DHA [27,33].

**3. BDNF**: A third reported neuroprotective effect of DHA is simply to increase the production of brain-derived neurotrophic factor (BDNF) [34], which is depleted in AD hippocampus and believed to be responsible for many of the positive effects of exercise on cognition [35].

**4. Antioxidant defenses**: A fourth class of neuroprotective effect comes from antioxidant activity, which may be direct as discussed by Yavin et al. [90], or indirect by induction of antioxidant defense enzymes (Table 3). Because omega-3 fatty acids are highly unsaturated fatty acids and subject to oxidative attack via autocatalytic feed-forward lipid peroxidation reactions, they need additional protection and appear to induce antioxidant defense enzymes. This may occur via transcriptional regulation by the Nrf2 > Keap > antioxidant response element pathway that is known to be regulated by PI3-K > Akt signaling [36]. Thus, DHA potentiation of Akt may promote antioxidant defenses. Whatever the mechanism, omega-3 fatty acids can reduce oxidative damage in AD model mice [33] and in humans [37]. This is significant because oxidative damage is clearly elevated in AD, including oxidative damage products of DHA itself [38–40].

**5. Neuroprotection D1 (NPD1)**: A fifth type of neuroprotective effect of DHA is mediated by a lipoxygenase metabolite of DHA, neuroprotectin D1 (NPD1) [41]. This metabolite has a variety of effects including up-regulation of anti-apoptotic and down-regulation of pro-apoptotic mediators that regulate caspases involved in cell death. It appears to be a very potent neuroprotective agent with multiple activities.

**6–11. Other neuroprotective functions:** Other potentially neuroprotective activities listed in Table 3 include (6) promoting neurogenesis, (7) increasing a glucose transporter, (8) coupling of blood flow to glucose utilization, (9) improving synaptic membrane fluidity, (10) improving G-protein coupling that is involved in many signal transduction pathways and (11) directly binding to lipid-related transcription factors including forms of LXR, RxR, and PPAR. It is unclear whether these direct transcriptional effects occur *in vivo* with DHA itself, because the EC50 for this type of mechanism may require higher levels of free DHA than other pathways [42]; however, these are possible targets for DHA metabolites. It is interesting to note that the insulin-sensitizing PPAR agonist rosaglitazone has been in clinical trials for AD and, reminiscent of fish epidemiology discussed above, showed protection in non-ApoE4 carriers [43].

These mechanistic studies in preclinical models suggest neuroprotective mechanisms. Some direct evidence for neuroprotection in people is suggested by a recent German study that showed improved survival and recovery from severe head injury when brain trauma patients received fish oil supplements through their parental feeding tubes [44].

## 6. Disease-specific mechanisms of DHA protection in Alzheimer disease

Most of the neuroprotective mechanisms discussed above are potentially relevant to AD and other neurodegenerative diseases or CNS damage. However, since AD is believed to be initiated by Aβ peptide, many potential AD treatments are aimed at inhibiting Aβ production, for example: secretase inhibitors and modulators. DHA's efficacy in reducing Aβ production/amyloid accumulation *in vitro* and in animal models has now been observed by eight out

**Table 4**
DHA reduces production of the amyloid β protein that is believed to cause AD (8/9 studies).

| Effect of omega-3 on Aβ/amyloid | Reference |
| --- | --- |
| (1) Reduced Aβ production—human neurons | [93] |
| (2) Reduced Aβ pathway products | [100] |
| (3) Reduced Aβ production—cell lines | [29] |
| (4) Reduced amyloid accumulation *in vivo* | [101] |
| (5) Reduced amyloid accumulation *in vivo* | [29] |
| (6) Reduced amyloid accumulation *in vivo* | [102] |
| (7) Reduced intraneuronal Aβ *in vivo* | [28] |
| (8) Reduced amyloid *in vivo* | [103] |
| (9) No effect on amyloid (or brain DHA) | [45] |

of nine studies (Table 4). In the one study that did not see a reduction in Aβ, the supplemented diet also failed to change brain DHA or AA levels [45].

DHA appears to reduce Aβ production by several mechanisms, including the induction of increased neuronal expression of SorLa/LR11 in multiple model systems *in vitro* and *in vivo* [46]. SorLa is an amyloid precursor sorting protein with diminished expression levels in surviving neurons at early stages of late onset AD, but not early onset familial AD [47]. Because SorLa (also called LR11) is known to limit Aβ production by trafficking amyloid precursor proteins away from the secretases that make Aβ, reduced levels of LR11 would be predicted to play a causal role to increase AD risk. There is some genetic evidence to support this hypothesis [48–51].

Whether or not genetic variants that limit expression of LR11 contribute to late onset AD, the majority of patients have reductions in expression. Omega-3 fatty acids appear to be one known environmental risk factor that can up-regulate SorLA/LR11 expression in animal models. We have recently found that soluble forms of LR11 can be detected in human CSF, and that deficits occur in AD patients [52]. It will be worth evaluating CSF LR11 levels in clinical trials with DHA treatment.

There are several other candidate mechanisms for DHA-reducing amyloid. DHA may also be able to lower Aβ by reducing expression of presenilin 1 and γ-secretase activity [28]. Omega-3 fatty acids in fish oil are also reported to increase expression of an Aβ-clearing transport protein, transthyretin (TTR) [53]. Finally, because expression of a major Aβ-degrading enzyme, the insulin-degrading enzyme (IDE), is regulated by the PI3-K> Akt pathway, DHA may increase IDE expression and Aβ clearance [54].

## 7. DHA protects from Aβ oligomer toxicity to synapses

Consistent with DHA's many neuroprotective mechanisms, it can protect against Aβ oligomer toxicity and caspase activation *in vitro* [55]. Lower doses of Aβ oligomers also cause loss of synapses without killing neurons. Recently, our group reported evidence for an Aβ oligomer-mediated defect in a pathway involving components implicated by different labs that were looking at Aβ oligomers *in vitro*. These included NMDA receptors, the tyrosine kinase fyn, Tiam1, rac, PAK, LIMK1, and, downstream, the actin-severing protein cofilin. This pathway is dysregulated in AD brain and regulates the oligomer-induced loss of dendritic spines in excitatory synapses *in vitro*, including the spine actin-binding protein drebrin [56]. Drebrin shows massive losses in AD temporal cortex and hippocampus, and DHA protects against this loss in a transgenic mouse model of AD [33]. We now have evidence that DHA is remarkably effective in protecting against oligomer-induced synaptic marker loss in primary neurons *in vitro*, by blocking this synaptotoxic signal transduction pathway regulating

dendritic spines and synapse formation (Q.L. Ma, F. Yang, E. Rosario, O.J. Ubeda, P.P. Chen, W. Beech, B. Hudspeth, S.A. Frautschy, G. M. Cole, manuscript in preparation). In our view, drebrin loss can be taken as an index of dysregulation of this pathway, and drebrin shows a precipitous loss in temporal cortex of AD brain as mild cognitive impairment emerges (MMSE >27) [57]. After that, it shows no further reduction. Since drebrin loss was the most DHA-sensitive endpoint in our AD animal model studies, these results suggest that DHA intervention will be most effective at the earliest stages of cognitive decline.

## 8. DHA limits tau kinases that promote tau pathology/neurofibrillary tangles

Neurofibrillary tangles are an AD pathology featuring intra-neuronal accumulation of filamentous aggregates of the micro-tubule protein tau. This pathology is promoted by Aβ aggregate-induced induction of "tau kinases" that phosphorylate tau to keep it off microtubules, and to promote exposure of β conformation stable regions that bind to each other to make proteolytically stable tau amyloid fibrils. Two of the major tau kinases that are induced by Aβ are GSK3β and JNK. GSK3β is negatively regulated by the PI3-K> Akt pathway that DHA potentiates, as discussed above. Thus, it is not surprising that in our amyloid plaque-forming AD model mice on DHA-depleting high safflower oil diets, this inhibitory GSK3β phosphorylation is suppressed, and this is reversed by DHA treatment restoring inhibitory control of GSK3β (Ma et al., unpublished). While this effect would be predicted to limit tangle formation, those AD model mice lack a human tau transgene that is required for tangles to develop. Using triple transgenic AD model mice with two genes that increase Aβ and a mutant human tau, LaFerla's group has shown that DHA not only slows the accumulation of the intraneuronal Aβ implicated in the model, it also suppresses the activity of JNK and the accumulation of abnormally phosphorylated tau [28]. Thus, DHA has multiple mechanisms for reducing both the amyloid peptide (Aβ) that initiates AD and the tau kinases and tau pathology that appear to perpetuate neurodegeneration. Coupled with more than 10 other neuroprotective effects listed in Table 3, DHA is very well positioned to play a causal role in preventing AD that can explain the positive epidemiology studies.

## 9. DHA protection is incomplete and should be combined with antioxidants

Nevertheless, despite profound anti-Alzheimer effects *in vitro* and in multiple AD animal models, DHA protection is incomplete. For example, in our late intervention model where it protected drebrin and CamKII alpha as it does with Aβ oligomer toxicity *in vitro*, DHA failed to protect NMDA receptor loss [27] and the ERK> CREB signal transduction pathway (Ma et al., unpublished). These results suggest that DHA treatment alone will likely have some benefits, but may work best in combination with other treatments. We have previously argued that oxidative damage in AD brains may be depleting DHA, suggesting a combination with an antioxidant treatment [33]. Anyone who has worked with DHA *in vitro*, knows that it needs to be protected by antioxidants, particularly at higher doses. While this is much less clear *in vivo*, where antioxidant defenses are usually sufficient, oxidation of supplemented DHA may be a problem in pathological environments [58]. DHA is better protected *in vivo*, but clearly not adequately protected in AD brain because, as reviewed above, its F-4 isoprostane products are elevated. DHA's lipid peroxidation products like bifunctional aldehydes can cross-link proteins,

including tau proteins [59]. Further, specific toxic oxidized forms of DHA have recently been identified [60]. One might predict lipid peroxidation to be an issue in AD because Aβ aggregates are known to increase oxidative damage, and AD has increased mitochondrial defects and elevation of most known oxidative damage markers (reviewed in [33]). Since Aβ aggregates accumulate in synapses [61], and this is where peroxidizable DHA is concentrated in areas of high metabolism and even in the mitochondria [62], there is every reason to expect the observed increase in DHA oxidation products in AD brain and CSF. Given that DHA is so readily oxidized, there is a very strong rationale suggesting that it be combined with antioxidant interventions like the classical vitamin E plus C or the more brain permeable and mitochondrial-protective alpha lipoic acid. Our group has also advocated that it be combined with the polyphenolic antioxidant curcumin, because it has additional anti-amyloid and AD protective activities [63].

## 10. Clinical trials

Collectively, the strong positive epidemiology and preclinical data have led to multiple clinical trials for the treatment or prevention of AD with omega-3 fatty acids, notably DHA (Table 5).

Results to-date suggest that DHA alone may produce some benefits, but may not work well by itself in cases of established AD with MMSE <26; however, it may be effective with early intervention by itself (MCI), or even in established AD in combination with an antioxidant. For example, in a small Japanese trial from Kotani [64] as well as in the completed Swedish trial from Freund-Levi [65] and in a similar small 6-month Taiwanese trial from Chiu [66], DHA or fish oil appeared to stabilize MMSE in the MCI patients, but not in those with established AD. It is encouraging that in the only example of a DHA/antioxidant combination treatment approach, a pilot alpha lipoate/fish oil trial from Shinto and colleagues at OHSU (NCT000904029), MMSE was significantly stabilized over a 12-month period [67]. If this level of efficacy is confirmed in larger trials, this will be a remarkable and cost-effective treatment. While these are the first trials to report, they are encouraging; additional trials are registered at www.clinical.trials.gov and ongoing (Table 6).

From the perspective of this review, it is unfortunate that none of the ongoing trials combine DHA with an antioxidant. The ADCS trial with DHA includes AD patients with MMSE 26 or below and

**Table 5**
Omega-3 fatty acids in clinical trials for AD treatment or prevention.

| Clinical trials—completed | Reference |
| --- | --- |
| 240 mg/day DHA+AA (3 mos) improved memory and attention in amnestic MCI ($n = 12$) (but not AD ($N = 8$)) | [64] |
| 4 g fish oil (1.7 g DHA for 6 months, $n = 174$) ; no sig. effect for MMSE <27, but improved delayed recall, attention; MMSE >27 stabilized with w-3 ($n = 32$) | [65] |
| Memo trial, normal or MMSE >21 ($n = 302$ , 65+ years, 1800 vs 400 mg EPA+DHA vs placebo for 26 weeks)—increases in attention, especially in E4+ and men, but no change in cognition | [104] |
| 6 months 1.8 g/day total n-3 g showed improvement in ADAS-cog compared to olive oil with MCI ($p = 0.03$), No effect in AD; NCT00628017 | [66] |
| OHSU pilot, MMSE 15-26 ($n = 39$, fish oil (750 mg DHA, 1050 EPA ±600 mg alpha lipoate vs placebo)—FO+ lipoate-stabilized MMSE, ADLs ($p = 0.02$), NCT00090402 | [67] |

*Abbreviations*: ADLs, activities of daily living; AA, arachidonic acid; FO, fish oil; MCI, mild cognitive impairment; OHSU, Oregon Health State University.

**Table 6**
Ongoing clinical trials (2008).

| Ongoing trials | PI. |
| --- | --- |
| OPAL trial, cognitive decline, age 70–79 MMSE >24, 500 mg DHA+200 mg EPA ($n = 800$): UK identifier: ISRCTN72331636 | Dangour et al., 2006 (UK) [105] |
| ADCS trial, mild to mod AD −2 g algal DHA/day for 18 months ($n = 400$) , NCT00440050 | J. Quinn, OHSU (NIA/ADCS/ Martek) |
| MIDAS Early memory deficits, 900 mg/d, 6 months ($n = 465$); NCT00278135 | K. Yurko-Mauro (Martek Biosciences) |
| Primary Prevention of cognitive decline in frail elderly, MMSE >24, $n = 1200$, omega 3 (VO137), 800 mg DHA/ d 3 years BCT00672685 | B. Vellas, University Hospital, Toulouse |

*Abbreviations*: ADCS, AD cooperative studies; OPAL, older people and n-3 long-chain polyunsaturated fatty acids; MMSE, mini-mental state examination; MIDAS, Memory Improvement with Docosahaenoic acid study.

is for an 18-month duration. It is larger and longer than the completed 6-month Freund-Levi et al. treatment trial in Sweden, which failed to show clear cognitive benefit in similarly advanced AD patients. But the ADCS trial excludes MCI patients who are the most likely to benefit. Nevertheless, some 68% of the patients in the Freund-Levi trial were ApoE4 positive, and some of the epidemiology suggests that they may respond poorly. Therefore, there is hope for some positive results in the larger ADCS trial that may either take longer to manifest, or are ApoE genotype dependent and require the larger patient pool. Further, since EPA can competitively reduce DHA incorporation, there may or may not be benefits from enhancing DHA delivery by using a slightly higher dose of algal DHA, rather than a fish oil product, and thus avoiding having EPA in the formulation. We must await the trial result.

We would strongly advocate a combination approach in future planned trials with AD patients. We have argued for this on a theoretical basis and based on our preclinical results, but the positive data from the small OHSU pilot make this approach much more plausible. Despite these concerns, there is sufficient evidence to expect some significant protective effects, particularly with the early intervention efforts in three of the ongoing trials.

Is DHA an essential nutrient? The counterargument is that dietary ALA provides sufficient DHA. As reviewed here, the epidemiology of fish and to a lesser extent DHA intake provide a strong case for protection from cognitive decline and dementia by higher intakes of marine omega 3 fatty acids than much of the population is achieving from other dietary n-3. The hypothesis that conversion from dietary ALA provides adequate DHA or EPA, does not explain the epidemiology showing protection from higher marine sources. Further, DHA rather than EPA is markedly enriched in the brain and the preclinical model data clearly implicate DHA as an effective protection against Alzheimer pathogenesis. That said, to-date there are only a handful of small randomized clinical trials with fish oil showing protection and only in early stages of disease. More definitive, longer and larger, adequately powered trials with DHA are needed to examine DHA efficacy against cognitive decline due to Alzheimer. Fortunately, several trials are already currently underway. However, age-related cognitive decline is also caused by vascular disease and there, the clinical trial data are fairly compelling. Large clinical trials have shown that fish oil supplements reduce death from cardiovascular disease (CVD) in patients with substantial risk [6]. Further, meta-analysis of the epidemiology of EPA+DHA intake shows similar protection from CVD death in healthy adults [68]. In contrast, we lack similar evidence to conclude that merely lowering the n-6/n-3 ratio with ALA protects from CVD [69]. This

is very strong evidence that CVD protective levels of EPA/DHA levels are not being derived from dietary ALA in the general population. While the relative roles for EPA and DHA in CVD and protection against stroke remain controversial [5], lowering the CVD death rate in our aging population is a compelling argument for an essential role for combined EPA+DHA, but neither n-3 fatty acid on its own.

## 11. Conclusions

The combination of a strong rationale from both positive epidemiology and preclinical trials have propelled omega-3 fatty acid supplements into multiple clinical trials for age-related cognitive decline and dementia, notably AD. Because dementia risk doubles with every 5 years over age 65, the caseload of AD and vascular dementia will more than double as the baby boomers age. Dementia is amongst the chronic age-related diseases, which is the most disabling, demanding the most intensive and expensive care and frequent institutionalization. Dementia alone can be predicted to drive the cost of Medicare and private health insurance up to the point where it becomes an unsustainable economic burden. Compared with most new medications, omega-3 fatty acids would be an outstanding intervention from long-term safety, side-effect, and cost perspectives. The evidence to-date from the small completed trials suggests possible efficacy both with early intervention and, in combination with antioxidants, in more established AD. Because of their outstanding safety profile, low cost, and proven efficacy in reducing mortality from cardiovascular disease, omega-3 fatty acids, and DHA in particular, are very attractive for prevention. This is particularly true in populations with typical Western diets like the US, where the average dietary intake of DHA is less than half that required in the epidemiology to reduce risk for either CVD or AD. The evidence for CVD alone is sufficient to begin to take steps to get our population out of the low omega-3 fatty acid intake, high-risk groups for these major diseases. For established AD, we are just beginning to learn how to use DHA supplements for treatment. They may not work well alone for late-stage AD, particularly in groups with high oxidative stress like ApoE4, so we can expect to combine DHA with other treatments, including antioxidants.

## References

[1] J.L. Cummings, G. Cole, Alzheimer disease, JAMA 287 (2002) 2335–2338.

[2] M. Fotuhi, P.P. Zandi, K.M. Hayden, A.S. Khachaturian, C.A. Szekely, H. Wengreen, R.G. Munger, M.C. Norton, J.T. Tschanz, C.G. Lyketsos, J.C. Breitner, K. Welsh-Bohmer, Better cognitive performance in elderly taking antioxidant vitamins E and C supplements in combination with nonsteroidal anti-inflammatory drugs: the Cache County Study, Alzheimers Dement 4 (2008) 223–227.

[3] C.A. Szekely, R.C. Green, J.C. Breitner, T. Ostbye, A.S. Beiser, M.M. Corrada, H.H. Dodge, M. Ganguli, C.H. Kawas, L.H. Kuller, B.M. Psaty, S.M. Resnick, P.A. Wolf, A.B. Zonderman, K.A. Welsh-Bohmer, P.P. Zandi, No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies, Neurology 70 (2008) 2291–2298.

[4] G.M. Cole, T. Morihara, G.P. Lim, F. Yang, A. Begum, S.A. Frautschy, NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models, Ann. N. Y. Acad. Sci. 1035 (2004) 68–84.

[5] W.S. Harris, M. Miller, A.P. Tighe, M.H. Davidson, E.J. Schaefer, Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives, Atherosclerosis 197 (2008) 12–24.

[6] J.H. Lee, J.H. O'Keefe, C.J. Lavie, R. Marchioli, W.S. Harris, Omega-3 fatty acids for cardioprotection, Mayo Clin. Proc. 83 (2008) 324–332.

[7] C. Rosendorff, M.S. Beeri, J.M. Silverman, Cardiovascular risk factors for Alzheimer's disease, Am. J. Geriatr. Cardiol. 16 (2007) 143–149.

[8] D. Mozaffarian, E.B. Rimm, Fish intake, contaminants, and human health: evaluating the risks and the benefits, JAMA 296 (2006) 1885–1899.

[9] J.H. Lee, J.H. O'Keefe, C.J. Lavie, R. Marchioli, W.S. Harris, Omega3 fatty acids for cardioprotection, Mayo Clin. Proc. 83 (2008) 324–332.

[10] C. Maclean, A. Issa, S. Newberry, W. Mojica, S. Morton, R. Garland, L. Hilton, S. Traina, P. Shekelle, Effects of omega-3 fatty acids on cognitive function with aging, dementia, and neurological diseases, Evid. Rep. Technol. Assess (Summ.) (2005) 1–88.

[11] E.J. Schaefer, V. Bongard, A.S. Beiser, S. Lamon-Fava, S.J. Robins, R. Au, K.L. Tucker, D.J. Kyle, P.W. Wilson, P.A. Wolf, Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study, Arch. Neurol. 63 (2006) 1545–1550.

[12] M.A. Beydoun, J.S. Kaufman, P.D. Sloane, G. Heiss, J. Ibrahim, n-3 Fatty acids, hypertension and risk of cognitive decline among older adults in the Atherosclerosis Risk in Communities (ARIC) study, Public Health Nutr. 11 (2008) 17–29.

[13] W. Wang, L. Shinto, W.E. Connor, J.F. Quinn, Nutritional biomarkers in Alzheimer's disease: the association between carotenoids, n-3 fatty acids, and dementia severity, J. Alzheimers. Dis. 13 (2008) 31–38.

[14] L.J. Whalley, I.J. Deary, J.M. Starr, K.W. Wahle, K.A. Rance, V.J. Bourne, H.C. Fox, n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: an observational follow-up study in late adulthood, Am. J. Clin. Nutr. 87 (2008) 449–454.

[15] K.S. Montine, P.J. Kim, S.J. Olson, W.R. Markesbery, T.J. Montine, 4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease, J. Neuropathol. Exp. Neurol. 56 (1997) 866–871.

[16] C. Ramassamy, D. Averill, U. Beffert, L. Theroux, S. Lussier-Cacan, J.S. Cohn, Y. Christen, A. Schoofs, J. Davignon, J. Poirier, Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain, Neurobiol. Dis. 7 (2000) 23–37.

[17] L. Jofre-Monseny, A.M. Minihane, G. Rimbach, Impact of apoE genotype on oxidative stress, inflammation and disease risk, Mol. Nutr. Food Res. 52 (2008) 131–145.

[18] E. Masliah, L. Crews, L. Hansen, Synaptic remodeling during aging and in Alzheimer's disease, J. Alzheimers Dis. 9 (2006) 91–99.

[19] N. Salem Jr, B. Litman, H.Y. Kim, K. Gawrisch, Mechanisms of action of docosahexaenoic acid in the nervous system, Lipids 36 (2001) 945–959.

[20] H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, N.E. Cooper, P. Eikelenboom, M. Emmerling, B.L. Fiebich, C.E. Finch, S. Frautschy, W.S. Griffin, H. Hampel, M. Hull, G. Landreth, L. Lue, R. Mrak, I.R. Mackenzie, P.L. McGeer, M.K. O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyoma, F.L. Van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Wegrzyniak, G. Wenk, T. Wyss-Coray, Inflammation and Alzheimer's disease, Neurobiol. Aging 21 (2000) 383–421.

[21] J.J. Palop, J. Chin, E.D. Roberson, J. Wang, M.T. Thwin, N. Bien-Ly, J. Yoo, K.O. Ho, G.Q. Yu, A. Kreitzer, S. Finkbeiner, J.L. Noebels, L. Mucke, Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease, Neuron 55 (2007) 697–711.

[22] L. Ho, C. Pieroni, D. Winger, D.P. Purohit, P.S. Aisen, G.M. Pasinetti, Regional distribution of cyclo-oxygenase-2 in the hippocampal formation in Alzheimer's disease, J. Neurosci. Res. 57 (1999) 295–303.

[23] W.J. Lukiw, N.G. Bazan, Cycloxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex, J. Neurosci. Res. 50 (1997) 937–945.

[24] T.J. Montine, K.R. Sidell, B.C. Crews, W.R. Markesbery, L.J. Marnett, L.J. Roberts 2nd, J.D. Morrow, Elevated CSF prostaglandin E2 levels in patients with probable AD, Neurology 53 (1999) 1495–1498.

[25] D. Pratico, V. Zhukareva, Y. Yao, K. Uryu, C.D. Funk, J.A. Lawson, J.Q. Trojanowski, V.M. Lee, 12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress, Am. J. Pathol. 164 (2004) 1655–1662.

[26] O. Firuzi, J. Zhuo, C.M. Chinnici, T. Wisniewski, D. Pratico, 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease, FASEB J. 22 (2008) 1169–1178.

[27] F. Calon, G.P. Lim, T. Morihara, F. Yang, O. Ubeda, N.J. Salem, S.A. Frautschy, G.M. Cole, Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease, Eur. J. Neurosci. 22 (2005) 617–626.

[28] K.N. Green, H. Martinez-Coria, H. Khashwji, E.B. Hall, K.A. Yurko-Mauro, L. Ellis, F.M. LaFerla, Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels, J. Neurosci. 27 (2007) 4385–4395.

[29] M. Oksman, H. Iivonen, E. Hogyes, Z. Amtul, B. Penke, I. Leenders, L. Broersen, D. Lutjohann, T. Hartmann, H. Tanila, Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid

accumulation in APP/PS1 transgenic mice, Neurobiol. Dis. 23 (2006) 563–572.

[30] L.A. Kotilinek, M.A. Westerman, Q. Wang, K. Panizzon, G.P. Lim, A. Simonyi, S. Lesne, A. Falinska, L.H. Younkin, S.G. Younkin, M. Rowan, J. Cleary, R.A. Wallis, G.Y. Sun, G. Cole, S. Frautschy, R. Anwyl, K.H. Ashe, Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity, Brain 131 (2008) 651–664.

[31] S.C. Vlad, D.R. Miller, N.W. Kowall, D.T. Felson, Protective effects of NSAIDs on the development of Alzheimer disease, Neurology 70 (2008) 1672–1677.

[32] M. Akbar, F. Calderon, Z. Wen, H.Y. Kim, Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival, Proc. Natl. Acad. Sci. USA 102 (2005) 10858–10863.

[33] F. Calon, G.P. Lim, F. Yang, T. Morihara, B. Teter, O. Ubeda, P. Rostaing, A. Triller, N. Salem Jr, K.H. Ashe, S.A. Frautschy, G.M. Cole, Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model, Neuron 43 (2004) 633–645.

[34] J.S. Rao, R.N. Ertley, H.J. Lee, J.C. DeMar Jr, J.T. Arnold, S.I. Rapoport, R.P. Bazinet, n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism, Mol. Psychiatry 12 (2007) 36–46.

[35] S.A. Neeper, F. Gómez-Pinilla, J. Choi, C.W. Cotman, Exercise and brain neurotrophins, Nature 373 (1995) 109.

[36] J.M. Lee, J.A. Johnson, An important role of Nrf2-ARE pathway in the cellular defense mechanism, J. Biochem. Mol. Biol. 37 (2004) 139–143.

[37] T.A. Mori, I.B. Puddey, V. Burke, K.D. Croft, D.W. Dunstan, J.H. Rivera, L.J. Beilin, Effect of omega 3 fatty acids on oxidative stress in humans: GC–MS measurement of urinary F2-isoprostane excretion, Redox. Rep. 5 (2000) 45–46.

[38] D. Praticò, V.M.Y. Lee, J.Q. Trojanowski, J. Rokach, G.A. Fitzgerald, Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo, FASEB J. 12 (1998) 1777–1783.

[39] J. Nourooz-Zadeh, E.H.C. Liu, B. Yhlen, E.E. Anggard, B. Halliwell, F4-Isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease, J. Neurochem. 72 (1999) 734–740.

[40] E.E. Reich, W.R. Markesbery, L.J. Roberts 2nd, L.L. Swift, J.D. Morrow, T.J. Montine, Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease, Am. J. Pathol. 158 (2001) 293–297.

[41] N.G. Bazan, Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress, Brain Pathol. 15 (2005) 159–166.

[42] F. Calderon, H.Y. Kim, Role of RXR in neurite outgrowth induced by docosahexaenoic acid, Prostaglandins Leukot. Essent. Fatty Acids 77 (2007) 227–232.

[43] M.E. Risner, A.M. Saunders, J.F. Altman, G.C. Ormandy, S. Craft, I.M. Foley, M.E. Zvartau-Hind, D.A. Hosford, A.D. Roses, Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease, Pharmacogenom. J. (2006).

[44] A.R. Heller, S. Rossler, R.J. Litz, S.N. Stehr, S.C. Heller, R. Koch, T. Koch, Omega-3 fatty acids improve the diagnosis-related clinical outcome*, Crit. Care Med. (2006) Publish Ahead of Print.

[45] G.W. Arendash, M.T. Jensen, N. Salem Jr, N. Hussein, J. Cracchiolo, A. Dickson, R. Leighty, H. Potter, A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice, Neuroscience 149 (2007) 286–302.

[46] Q.L. Ma, B. Teter, O.J. Ubeda, T. Morihara, D. Dhoot, M.D. Nyby, M.L. Tuck, S.A. Frautschy, G.M. Cole, Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention, J. Neurosci. 27 (2007) 14299–14307.

[47] K.L. Sager, J. Wuu, S.E. Leurgans, M.H. Rees, M. Gearing, E.J. Mufson, A.I. Levey, J.J. Lah, Neuronal LR11/sorLA expression is reduced in mild cognitive impairment, Ann. Neurol. 62 (2007) 640–647.

[48] E. Rogaeva, Y. Meng, J.H. Lee, Y. Gu, T. Kawarai, F. Zou, T. Katayama, C.T. Baldwin, R. Cheng, H. Hasegawa, F. Chen, N. Shibata, K.L. Lunetta, R. Pardossi-Piquard, C. Bohm, Y. Wakutani, L.A. Cupples, K.T. Cuenco, R.C. Green, L. Pinessi, I. Rainero, S. Sorbi, A. Bruni, R. Duara, R.P. Friedland, R. Inzelberg, W. Hampe, H. Bujo, Y.Q. Song, O.M. Andersen, T.E. Willnow, N. Graff-Radford, R.C. Petersen, D. Dickson, S.D. Der, P.E. Fraser, G. Schmitt-Ulms, S. Younkin, R. Mayeux, L.A. Farrer, P. St George-Hyslop, The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease, Nat. Genet. 39 (2007) 168–177.

[49] Y. Meng, J.H. Lee, R. Cheng, P. St George-Hyslop, R. Mayeux, L.A. Farrer, Association between SORL1 and Alzheimer's disease in a genome-wide study, Neuroreport 18 (2007) 1761–1764.

[50] J.H. Lee, R. Cheng, N. Schupf, J. Manly, R. Lantigua, Y. Stern, E. Rogaeva, Y. Wakutani, L. Farrer, P. St George-Hyslop, R. Mayeux, The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort, Arch. Neurol. 64 (2007) 501–506.

[51] J.H. Lee, R. Cheng, L.S. Honig, J.P. Vonsattel, L. Clark, R. Mayeux, Association between genetic variants in SORL1 and autopsy-confirmed Alzheimer disease, Neurology 70 (2008) 887–889.

[52] Q.-L. Ma, D.R. Galasko, J.M. Ringman, H.V. Vinters, S.D. Edland, J. Pomakian, O.J. Ubeda, E.R. Rosario, B. Teter, S.A. Frautschy, G.M. Cole, Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid, Arch. Neurol. 66 (2009) 1–10.

[53] L.G. Puskas, K. Kitajka, C. Nyakas, G. Barcelo-Coblijn, T. Farkas, Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus, Proc. Natl. Acad. Sci. USA (2003).

[54] L. Zhao, B. Teter, T. Morihara, G.P. Lim, S.S. Ambegaokar, O.J. Ubeda, S.A. Frautschy, G.M. Cole, Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention, J. Neurosci. 24 (2004) 11120–11126.

[55] S. Florent, C. Malaplate-Armand, I. Youssef, B. Kriem, V. Koziel, M.C. Escanye, A. Fifre, I. Sponne, B. Leininger-Muller, J.L. Olivier, T. Pillot, T. Oster, Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers, J. Neurochem. 96 (2006) 385–395.

[56] Q.L. Ma, F. Yang, F. Calon, O.J. Ubeda, J.E. Hansen, R.H. Weisbart, W. Beech, S.A. Frautschy, G.M. Cole, p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis, J. Biol. Chem. 283 (2008) 14132–14143.

[57] S.E. Counts, M. Nadeem, S.P. Lad, J. Wuu, E.J. Mufson, Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment, J. Neuropathol. Exp. Neurol. 65 (2006) 592–601.

[58] D.Y. Yang, H.C. Pan, Y.J. Yen, C.C. Wang, Y.H. Chuang, S.Y. Chen, S.Y. Lin, S.L. Liao, S.L. Raung, C.W. Wu, M.C. Chou, A.N. Chiang, C.J. Chen, Detrimental effects of post-treatment with fatty acids on brain injury in ischemic rats, Neurotoxicology 28 (2007) 1220–1229.

[59] T.C. Gamblin, M.E. King, J. Kuret, R.W. Berry, L.I. Binder, Oxidative regulation of fatty acid-induced tau polymerization, Biochemistry 39 (2000) 14203–14210.

[60] E.K. Long, T.C. Murphy, L.J. Leiphon, J. Watt, J.D. Morrow, G.L. Milne, J.R. Howard, M.J. Picklo Sr, Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6; n-3) acid oxidation, J. Neurochem. 105 (2008) 714–724.

[61] K.H. Gylys, J.A. Fein, F. Yang, D.J. Wiley, C.A. Miller, G.M. Cole, Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence, Am. J. Pathol. 165 (2004) 1809–1817.

[62] J.T. Brenna, G.Y. Diau, The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition, Prostaglandins Leukot. Essent. Fatty Acids 77 (2007) 247–250.

[63] G.M. Cole, S.A. Frautschy, Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model, Nutr. Health 18 (2006) 249–259.

[64] S. Kotani, E. Sakaguchi, S. Warashina, N. Matsukawa, Y. Ishikura, Y. Kiso, M. Sakakibara, T. Yoshimoto, J. Guo, T. Yamashima, Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction, Neurosci. Res. 56 (2006) 159–164.

[65] Y. Freund-Levi, M. Eriksdotter-Jonhagen, T. Cederholm, H. Basun, G. Faxen-Irving, A. Garlind, I. Vedin, B. Vessby, L.O. Wahlund, J. Palmblad, Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial, Arch. Neurol. 63 (2006) 1402–1408.

[66] C.C. Chiu, K.P. Su, T.C. Cheng, H.C. Liu, C.J. Chang, M.E. Dewey, R. Stewart, S.Y. Huang, The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study, Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 1538–1544.

[67] L. Shinto, J. Quinn, T. Montine, S. Baldauf-Wagner, B. Oken, D. Bourdette, J. Kaye, Omega-3 fatty acids and lipoic acid in Alzheimer's disease. Neurology 70 (2008) A393.

[68] W.S. Harris, P.M. Kris-Etherton, K.A. Harris, Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults, Curr. Atheroscler. Rep. 10 (2008) 503–509.

[69] B.A. Griffin, How relevant is the ratio of dietary n-6 to n-3 polyunsaturated fatty acids to cardiovascular disease risk? Evidence from the OPTILIP study, Curr. Opin. Lipidol. 19 (2008) 57–62.

[70] S. Kalmijn, E. Feskens, L. Launer, D. Kromhout, Polyunsaturated fatty acids, antioxidants and cognitive function in very old men, Am. J. Epidemiol. 145 (1997) 33–41.

[71] S. Kalmijn, L.J. Launer, A. Ott, J.C. Witteman, A. Hofman, M.M. Breteler, Dietary fat intake and the risk of incident dementia in the Rotterdam Study, Ann. Neurol. 42 (1997) 776–782.

[72] M.C. Morris, D.A. Evans, J.L. Bienias, C.C. Tangney, D.A. Bennett, R.S. Wilson, N. Aggarwal, J. Schneider, Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease, Arch. Neurol. 60 (2003) 940–946.

[73] S. Kalmijn, M.P. van Boxtel, M. Ocke, W.M. Verschuren, D. Kromhout, L.J. Launer, Dietary intake of fatty acids and fish in relation to cognitive performance at middle age, Neurology 62 (2004) 275–280.

[74] M.C. Morris, D.A. Evans, C.C. Tangney, J.L. Bienias, R.S. Wilson, Fish consumption and cognitive decline with age in a large community study, Arch. Neurol. 62 (2005) 1849–1853.

[75] T.L. Huang, P.P. Zandi, K.L. Tucker, A.L. Fitzpatrick, L.H. Kuller, L.P. Fried, G.L. Burke, M.C. Carlson, Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4, Neurology 65 (2005) 1409–1414.

[76] E. Nurk, C.A. Drevon, H. Refsum, K. Solvoll, S.E. Vollset, O. Nygard, H.A. Nygaard, K. Engedal, G.S. Tell, A.D. Smith, Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study, Am. J. Clin. Nutr. 86 (2007) 1470–1478.

[77] P. Barberger-Gateau, C. Raffaitin, L. Letenneur, C. Berr, C. Tzourio, J.F. Dartigues, A. Alperovitch, Dietary patterns and risk of dementia: the Three-City cohort study, Neurology 69 (2007) 1921–1930.

[78] B.M. van Gelder, M. Tijhuis, S. Kalmijn, D. Kromhout, Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study, Am. J. Clin. Nutr. 85 (2007) 1142–1147.

[79] J.A. Conquer, M.C. Tierney, J. Zecevic, W.J. Bettger, R.H. Fisher, Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment, Lipids 35 (2000) 1305–1312.

[80] B. Heude, P. Ducimetiere, C. Berr, Cognitive decline and fatty acid composition of erythrocyte membranes—The EVA Study, Am. J. Clin. Nutr. 77 (2003) 803–808.

[81] D. Laurin, R. Verreault, J. Lindsay, E. Dewailly, B.J. Holub, Omega-3 fatty acids and risk of cognitive impairment and dementia, J. Alzheimers Dis. 5 (2003) 315–322.

[82] C. Dullemeijer, J. Durga, I.A. Brouwer, O. van de Rest, F.J. Kok, R.J. Brummer, M.P. van Boxtel, P. Verhoef, n 3 fatty acid proportions in plasma and cognitive performance in older adults, Am. J. Clin. Nutr. 86 (2007) 1479–1485.

[83] M.A. Beydoun, J.S. Kaufman, J.A. Satia, W. Rosamond, A.R. Folsom, Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study, Am. J. Clin. Nutr. 85 (2007) 1103–1111.

[84] A. Cherubini, C. Andres-Lacueva, A. Martin, F. Lauretani, A.D. Iorio, B. Bartali, A. Corsi, S. Bandinelli, M.P. Mattson, L. Ferrucci, Low plasma n-3 fatty acids and dementia in older persons: the InCHIANTI study, J. Gerontol. A Biol. Sci. Med. 62 (2007) 1120–1126.

[85] A.M. Tully, H.M. Roche, R. Doyle, C. Fallon, I. Bruce, B. Lawlor, D. Coakley, M.J. Gibney, Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case–control study, Br. J. Nutr. 89 (2003) 483–489.

[86] D. Tassoni, G. Kaur, R.S. Weisinger, A.J. Sinclair, The role of eicosanoids in the brain, Asia Pac. J. Clin. Nutr. 17 (Suppl. 1) (2008) 220–228.

[87] J.S. Rao, R.N. Ertley, J.C. DeMar Jr, S.I. Rapoport, R.P. Bazinet, H.J. Lee, Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex, Mol. Psychiatry 12 (2007) 151–157.

[88] D. Cao, B. Yang, L. Hou, J. Xu, R. Xue, L. Sun, C. Zhou, Z. Liu, Chronic daily administration of ethyl docosahexaenoate protects against gerbil brain ischemic damage through reduction of arachidonic acid liberation and accumulation, J. Nutr. Biochem. 18 (2007) 297–304.

[89] A. Wu, Z. Ying, F. Gomez-Pinilla, Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats, J. Neurotrauma 21 (2004) 1457–1467.

[90] E. Yavin, A. Brand, P. Green, Docosahexaenoic acid abundance in the brain: a biodevice to combat oxidative stress, Nutr. Neurosci. 5 (2002) 149–157.

[91] M. Hashimoto, Y. Tanabe, Y. Fujii, T. Kikuta, H. Shibata, O. Shido, Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats, J. Nutr. 135 (2005) 549–555.

[92] M.S. Hossain, M. Hashimoto, S. Gamoh, S. Masumura, Antioxidative effects of docosahexaenoic acid in the cerebrum versus cerebellum and brainstem of aged hypercholesterolemic rats, J. Neurochem. 72 (1999) 1133–1138.

[93] W.J. Lukiw, J.G. Cui, V.L. Marcheselli, M. Bodker, A. Botkjaer, K. Gotlinger, C.N. Serhan, N.G. Bazan, A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease, J. Clin. Invest. 115 (2005) 2774–2783.

[94] S.M. Innis, Dietary (n-3) fatty acids and brain development, J. Nutr. 137 (2007) 855–859.

[95] H. Tsukada, T. Kakiuchi, D. Fukumoto, S. Nishiyama, K. Koga, Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: a PET study in conscious monkeys, Brain Res. 862 (2000) 180–186.

[96] F. Pifferi, M. Jouin, J.M. Alessandri, U. Haedke, F. Roux, N. Perriere, I. Denis, M. Lavialle, P. Guesnet, n-3 Fatty acids modulate brain glucose transport in endothelial cells of the blood-brain barrier, Prostaglandins Leukot. Essent. Fatty Acids 77 (2007) 279–286.

[97] M. Hashimoto, S. Hossain, T. Shimada, O. Shido, Docosahexaenoic acid-induced protective effect against impaired learning in amyloid beta-infused rats is associated with increased synaptosomal membrane fluidity, Clin. Exp. Pharmacol. Physiol. 33 (2006) 934–939.

[98] B.J. Litman, S.L. Niu, A. Polozova, D.C. Mitchell, The role of docosahexaenoic acid containing phospholipids in modulating G protein-coupled signaling pathways: visual transduction, J. Mol. Neurosci. 16 (2001) 237–242 (discussion 279–284).

[99] O.A. Gani, I. Sylte, Molecular recognition of Docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha, J. Mol. Graph Model (2008).

[100] C. Sahlin, F.E. Pettersson, L.N. Nilsson, L. Lannfelt, A.S. Johansson, Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease, Eur. J. Neurosci. 26 (2007) 882–889.

[101] G.P. Lim, F. Calon, T. Morihara, F. Yang, B. Teter, O. Ubeda, N. Salem Jr, S.A. Frautschy, G.M. Cole, A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model, J. Neurosci. 25 (2005) 3032–3040.

[102] C.R. Hooijmans, F. Rutters, P.J. Dederen, G. Gambarota, A. Veltien, T. van Groen, L.M. Broersen, D. Lutjohann, A. Heerschap, H. Tanila, A.J. Kiliaan, Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD), Neurobiol. Dis. 28 (2007) 16–29.

[103] B. Berg, S. Perez, O. Lazarov, M. Nadeem, S. Sisodia, K. Moore, E. Mufson, The dietary omega-3 fatty acid DHA reduces cortical and striatal β-amyloid load in APPswe/PS1ΔE9 transgenic mice. Society for Neuroscience, 37 Abs. 857.6, 2007.

[104] O. Van de Rest, J. Geleijnse, F. Kok, W. van Staveren, C. Dullemeijer, M. OldeRikkert, A. Beekman, L. de Groot, Effect of fish oil on cognitive performance in older subjects: a randomized controlled trial, Neurology 71 (2008) 430–438.

[105] A.D. Dangour, F. Clemens, D. Elbourne, N. Fasey, A.E. Fletcher, P. Hardy, G.E. Holder, F.A. Huppert, R. Knight, L. Letley, M. Richards, A. Truesdale, M. Vickers, R. Uauy, A randomised controlled trial investigating the effect of n-3 long-chain polyunsaturated fatty acid supplementation on cognitive and retinal function in cognitively healthy older people: the Older People And n-3 Long-chain polyunsaturated fatty acids (OPAL) study protocol [ISRCTN72331636], Nutr. J. 5 (2006) 20.